Newsroom

For Press Inquiries

Contact:
Hillhurst Biopharmaceuticals
hillhurstpress@hillhurstbio.com

 

News Release Details

SAN DIEGO, CA - May 24, 2016.  Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises In Sickle Cell Disease.

SAN DIEGO, CA - December 1, 2015.  Hillhurst Biopharmaceuticals Receives SBIR Funding for Development of HBI-002 as a Cytoprotective Therapeutic in Acute Cerebral Injury.

LOS ANGELES, CA – June 24, 2015.  Hillhurst Biopharmaceuticals Was Selected to Presented at the 7th Annual Los Angeles Venture Association (LAVA) First Look LA Conference.

HOLLYWOOD, FL – April 12, 2015.  Hillhurst Biopharmaceuticals Was Selected to Present Pre-Clinical Research Data at the 9th Annual Foundation for Sickle Cell Disease Research Sickle Cell Disease Research and Educational Symposium. 

LOS ANGELES, CA – June 11, 2014.  Hillhurst Biopharmaceuticals Presented at the 6th Annual Los Angeles Venture Association (LAVA) First Look LA Conference.

NEW ORLEANS, LA – Dec. 9, 2013.  Hillhurst Biopharmaceuticals Presented Pre-Clinical Proof of Concept Data at the American Society of Hematology (ASH) Meeting.

LOS ANGELES, CA – Nov. 4, 2013.  Hillhurst Biopharmaceuticals Was Selected to Present at the 15th Annual Southern California Biomedical Council (SoCalBio) Investor & Partnership Conference. 

 

Targeting Debilitating and Life Threatening Inflammation